Dr. Tarsheen Sethi
Claim this profileYale University
Studies Cancer
Studies T-Cell Lymphoma
3 reported clinical trials
6 drugs studied
Area of expertise
1Cancer
CD30 positive
EZH2 negative
EZH2 positive
2T-Cell Lymphoma
CD30 positive
EZH2 negative
EZH2 positive
Affiliated Hospitals
Clinical Trials Tarsheen Sethi is currently running
Pembrolizumab + Brentuximab
for T-Cell Lymphoma
This is a single arm, open label, multicenter study phase 2 study of pembrolizumab and brentuximab in subjects with relapsed/refractory CD30 positive T-cell lymphoma (including peripheral T-cell lymphoma and cutaneous T-cell lymphoma) who have received at least one prior therapy. We hypothesize that this combination is effective and will produce an overall response rate of \~55%. Pembrolizumab and brentuximab will be administered for 16 cycles in subjects with responsive disease. Pembrolizumab will be continued for an additional 19 cycles (total 35 cycles). Response assessments will occur at pre-specified intervals. For the primary endpoint the response assessment after 3 cycles will be taken into consideration. Dose adjustments for specific toxicities with either drug are detailed in the protocol. Based on statistical analysis 32 subjects will need to be accrued to evaluate for disease response based on historical control.
Recruiting1 award Phase 2
Mogamulizumab + DA-EPOCH
for T-Cell Lymphoma
Single- arm Phase II study evaluating the combination of mogamulizumab (MOGA) added on top of standard of care dose adjusted EPOCH (DA-EPOCH) in patients with newly diagnosed or relapsed/refractory (for CTCL only) aggressive T cell lymphoma including patients with Adult T-cell leukemia/lymphoma (ATLL).
Recruiting1 award Phase 2
More about Tarsheen Sethi
Clinical Trial Related1 year of experience running clinical trials · Led 3 trials as a Principal Investigator · 2 Active Clinical TrialsTreatments Tarsheen Sethi has experience with
- DA-EPOCH Protocol
- Mogamulizumab
- Brentuximab Vedotin
- Pembrolizumab
- Belinostat
- Tazemetostat
Breakdown of trials Tarsheen Sethi has run
Cancer
T-Cell Lymphoma
Peripheral T-Cell Lymphoma
Non-Hodgkin's Lymphoma
Cutaneous T-Cell Lymphoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Tarsheen Sethi specialize in?
Tarsheen Sethi focuses on Cancer and T-Cell Lymphoma. In particular, much of their work with Cancer has involved CD30 positive patients, or patients who are EZH2 negative.
Is Tarsheen Sethi currently recruiting for clinical trials?
Yes, Tarsheen Sethi is currently recruiting for 2 clinical trials in New Haven Connecticut. If you're interested in participating, you should apply.
Are there any treatments that Tarsheen Sethi has studied deeply?
Yes, Tarsheen Sethi has studied treatments such as DA-EPOCH Protocol, Mogamulizumab, Brentuximab vedotin.
What is the best way to schedule an appointment with Tarsheen Sethi?
Apply for one of the trials that Tarsheen Sethi is conducting.
What is the office address of Tarsheen Sethi?
The office of Tarsheen Sethi is located at: Yale University, New Haven, Connecticut 06520 United States. This is the address for their practice at the Yale University.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.